Trofinetide
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Trofinetide?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Trofinetide, sold under the brand name Daybue, is a medication used for the treatment of Rett syndrome.[1] It is taken by mouth.[1]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Daybue |
Other names | NNZ-2566 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a623019 |
License data |
|
Routes of administration | By mouth |
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 84% |
Metabolism | Insignificant |
Elimination half-life | ~ 1.5 h |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
Chemical and physical data | |
Formula | C13H21N3O6 |
Molar mass | 315.326 g·mol−1 |
3D model (JSmol) | |
| |
|
Close
The most common adverse reactions include diarrhea and vomiting.[2]
Trofinetide was approved for medical use in the United States in March 2023.[1][2][3] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4]